Nonarteritic anterior ischemic optic neuropathy (NAION) is an acute ischemic injury of the anterior optic nerve causing sudden, usually painless vision loss. It is the most common acute optic neuropathy in older adults.
Ocular Therapeutix's Axpaxli outperformed low-dose Eylea in a Phase 3 trial for wet AMD, while Oculis Holding reported narrowed Q4 losses and expects Phase 3 trial readouts for OCS-01 in Q2 2026.
A nationwide study of US veterans with type 2 diabetes found semaglutide initiation more than doubled the risk of nonarteritic anterior ischemic optic neuropathy compared to SGLT2 inhibitors, though absolute risk remained low at 0.29%.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07330713 |
Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study |
COMPLETED | NA |
| NCT07240649 |
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications |
NOT_YET_RECRUITING | PHASE4 |
| NCT03547206 |
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) |
TERMINATED | PHASE2 |
| NCT01131104 |
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors |
COMPLETED | |
| NCT00561834 |
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy |
COMPLETED | PHASE1 |
| NCT00432393 |
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy |
COMPLETED | PHASE4 |
